| scholarly article | Q13442814 |
| P50 | author | Siham Sabri | Q57612301 |
| Janusz Rak | Q67256958 | ||
| Ahmad Chaddad | Q39934599 | ||
| P2093 | author name string | Bassam S Abdulkarim | |
| Brian Meehan | |||
| Bertrand Jean-Claude | |||
| Paul Daniel | |||
| P2860 | cites work | A distinct "side population" of cells with high drug efflux capacity in human tumor cells | Q24564100 |
| BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures | Q24606873 | ||
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 | ||
| IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Structural and functional features of central nervous system lymphatic vessels | Q27316769 | ||
| Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents | Q27777800 | ||
| Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. | Q27853362 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. | Q55463299 | ||
| Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor | Q57815290 | ||
| Abscopal effect of radiotherapy combined with immune checkpoint inhibitors | Q58773898 | ||
| Mismatch correction at O 6 -methylguanine residues in E. coli DNA | Q59049241 | ||
| DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance | Q73724513 | ||
| Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice | Q73812953 | ||
| Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma | Q90258590 | ||
| Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications | Q91345120 | ||
| Identification of a cancer stem cell in human brain tumors | Q28131688 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma | Q29615604 | ||
| A restricted cell population propagates glioblastoma growth after chemotherapy | Q29615605 | ||
| Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. | Q30249563 | ||
| CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. | Q30427255 | ||
| Improved survival time trends for glioblastoma using the SEER 17 population-based registries | Q33828439 | ||
| Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 | ||
| Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas | Q34399073 | ||
| Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair | Q34723491 | ||
| Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine | Q34999747 | ||
| Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma | Q35232507 | ||
| Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
| Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment | Q35787908 | ||
| Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide | Q35920638 | ||
| Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models | Q36059965 | ||
| The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas | Q36310665 | ||
| Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. | Q36673354 | ||
| Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model | Q38739262 | ||
| The Damaging Effect of Passenger Mutations on Cancer Progression | Q38768283 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Clonal evolution of glioblastoma under therapy. | Q39704836 | ||
| An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells | Q40250980 | ||
| Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase | Q40473972 | ||
| M2 macrophages are more resistant than M1 macrophages following radiation therapy in the context of glioblastoma | Q42700764 | ||
| Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy | Q42821853 | ||
| MGMT promoter hypermethylation in a series of 104 glioblastomas | Q43298120 | ||
| Chromatin marks shape mutation landscape at early stage of cancer progression | Q47094097 | ||
| Tumor Mutational Burden and Response Rate to PD-1 Inhibition. | Q47270933 | ||
| Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. | Q47903730 | ||
| Ionizing radiation induces O6-alkylguanine-DNA-alkyltransferase mRNA and activity in mouse tissues | Q48310488 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma | Q49359610 | ||
| Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization | Q50089383 | ||
| Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. | Q50116977 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Recurrence | Q1903551 |
| temozolomide | Q425088 | ||
| glioma | Q1365309 | ||
| P304 | page(s) | 41 | |
| P577 | publication date | 2019-02-04 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities | |
| P478 | volume | 9 |
| Q100945825 | BET degrader inhibits tumor progression and stem-like cell growth via Wnt/β-catenin signaling repression in glioma cells |
| Q91820401 | CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells |
| Q90380770 | Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy |
| Q97555747 | Human genes differ by their UV sensitivity estimated through analysis of UV-induced silent mutations in melanoma |
| Q92675121 | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells |
| Q93167485 | Long Non-coding RNA EPIC1 Promotes Cell Proliferation and Motility and Drug Resistance in Glioma |
| Q99630184 | Micheliolide suppresses the viability, migration and invasion of U251MG cells via the NF-κB signaling pathway |
| Q92004993 | Modulation of N-Methyl-N-nitrosourea Mutagenesis in Mouse Embryo Fibroblasts Derived from the gpt Delta Mouse by an Inhibitor of the O6-Methylguanine Methyltransferase, MGMT |
| Q96155628 | Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma |
| Q91790776 | Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide |
| Q99413885 | Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme |
| Q89684724 | The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas |
| Q91736360 | circKIF4A promotes tumorogenesis of glioma by targeting miR-139-3p to activate Wnt5a signaling |
| Q90160575 | miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7 |
Search more.